Blue Fin Capital Inc. Grows Stock Position in Amgen Inc. (NASDAQ:AMGN)

Blue Fin Capital Inc. increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 30.4% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 6,142 shares of the medical research company’s stock after acquiring an additional 1,431 shares during the quarter. Blue Fin Capital Inc.’s holdings in Amgen were worth $1,601,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently added to or reduced their stakes in AMGN. Beck Mack & Oliver LLC raised its holdings in shares of Amgen by 0.7% during the fourth quarter. Beck Mack & Oliver LLC now owns 4,623 shares of the medical research company’s stock valued at $1,205,000 after acquiring an additional 34 shares during the last quarter. Continuum Advisory LLC increased its position in shares of Amgen by 0.7% during the fourth quarter. Continuum Advisory LLC now owns 5,154 shares of the medical research company’s stock worth $1,343,000 after purchasing an additional 35 shares in the last quarter. Blossom Wealth Management raised its stake in Amgen by 3.5% in the 4th quarter. Blossom Wealth Management now owns 1,090 shares of the medical research company’s stock valued at $284,000 after purchasing an additional 37 shares during the last quarter. Zullo Investment Group Inc. grew its holdings in shares of Amgen by 2.8% during the fourth quarter. Zullo Investment Group Inc. now owns 1,364 shares of the medical research company’s stock worth $356,000 after buying an additional 37 shares in the last quarter. Finally, Trillium Asset Management LLC raised its position in shares of Amgen by 4.2% in the fourth quarter. Trillium Asset Management LLC now owns 911 shares of the medical research company’s stock valued at $237,000 after buying an additional 37 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Insider Activity at Amgen

In other Amgen news, EVP David M. Reese sold 25,225 shares of Amgen stock in a transaction on Friday, February 21st. The shares were sold at an average price of $304.44, for a total value of $7,679,499.00. Following the transaction, the executive vice president now directly owns 36,922 shares in the company, valued at approximately $11,240,533.68. The trade was a 40.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.76% of the stock is owned by corporate insiders.

Amgen Price Performance

AMGN stock opened at $271.34 on Thursday. The business’s 50-day moving average is $288.67 and its two-hundred day moving average is $287.36. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The firm has a market capitalization of $145.90 billion, a P/E ratio of 35.94, a P/E/G ratio of 2.63 and a beta of 0.51. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.72. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The firm had revenue of $8.15 billion for the quarter, compared to analysts’ expectations of $8.05 billion. During the same quarter last year, the company earned $3.96 earnings per share. The firm’s revenue was up 9.4% compared to the same quarter last year. Analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be paid a dividend of $2.38 per share. The ex-dividend date is Friday, May 16th. This represents a $9.52 annualized dividend and a yield of 3.51%. Amgen’s dividend payout ratio is currently 86.86%.

Analyst Ratings Changes

A number of analysts have commented on the stock. Mizuho increased their price objective on shares of Amgen from $235.00 to $280.00 and gave the company a “neutral” rating in a report on Wednesday, May 7th. Bank of America boosted their price objective on shares of Amgen from $275.00 to $294.00 and gave the company an “underperform” rating in a report on Wednesday, March 5th. StockNews.com upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a report on Sunday. Citigroup reiterated a “neutral” rating on shares of Amgen in a report on Wednesday, February 5th. Finally, Cantor Fitzgerald assumed coverage on Amgen in a research note on Tuesday, April 22nd. They set a “neutral” rating and a $305.00 price target on the stock. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $309.22.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.